U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C23H25ClFN7O
Molecular Weight 469.942
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANDOTINIB

SMILES

CC1=CC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN5CCOCC5)=C2)=NN1

InChI

InChIKey=SQSZANZGUXWJEA-UHFFFAOYSA-N
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

HIDE SMILES / InChI

Molecular Formula C23H25ClFN7O
Molecular Weight 469.942
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.pharmacodia.com/yaodu/html/v1/chemicals/6eab78f10219a83895b2e2d71dc0656e.html | https://www.ncbi.nlm.nih.gov/pubmed/23317159 | https://www.ncbi.nlm.nih.gov/pubmed/22227528

An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. Gandotinib is in phase II clinical trials by Lilly for the treatment of myeloproliferative disorders.

Originator

Curator's Comment: # Eli Lilly

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.055 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
154 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GANDOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
753 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GANDOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.82 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GANDOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

120 mg administered once daily for 6 cycles (168 days).
Route of Administration: Oral
LY2784544 effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55 nM, respectively). In comparison, LY2784544 was much less potent at inhibiting interleukin-3-stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50=1183 and 1309 nM, respectively).
Substance Class Chemical
Created
by admin
on Wed Apr 02 06:53:35 GMT 2025
Edited
by admin
on Wed Apr 02 06:53:35 GMT 2025
Record UNII
ANC71R916O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
gandotinib [INN]
Preferred Name English
GANDOTINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
Gandotinib [WHO-DD]
Common Name English
3-(4-CHLORO-2-FLUOROBENZYL)-2-METHYL-N-(5-METHYL-1H-PYRAZOL-3-YL)-8- (MORPHOLINOMETHYL)IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE
Systematic Name English
IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE, 3-((4-CHLORO-2-FLUOROPHENYL)METHYL)-2-METHYL-N-(5- METHYL-1H-PYRAZOL-3-YL)-8-(4-MORPHOLINYLMETHYL)-
Common Name English
LY2784544
Code English
GANDOTINIB [USAN]
Common Name English
3-((4-CHLORO-2-FLUOROPHENYL)METHYL)-2-METHYL-N-(5-METHYL-1H-PYRAZOL-3-YL)-8- (MORPHOLIN-4-YLMETHYL)IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE
Systematic Name English
LY-2784544
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 334211
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
NCI_THESAURUS C1967
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
NCI_THESAURUS C129825
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL2107823
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
EVMPD
SUB128915
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
FDA UNII
ANC71R916O
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
WIKIPEDIA
Gandotinib
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
USAN
ZZ-54
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
DRUG BANK
DB13040
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
SMS_ID
100000155073
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
NCI_THESAURUS
C116857
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
INN
9695
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID20153789
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
PUBCHEM
46213929
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
CAS
1229236-86-5
Created by admin on Wed Apr 02 06:53:35 GMT 2025 , Edited by admin on Wed Apr 02 06:53:35 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
KI (nM) as determined in a kinetic ATP-based mechanism of action assay;
COMPETITIVE INHIBITOR
Ki
TARGET->WEAK INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
Biochemical measurement of JAK inhibition; Used JAK LanthaScreen Kinase assay.
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
Cellular assay; EPO TF-1 JAK2; Used Cellomics detection format.
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
TARGET->WEAK INHIBITOR
cellular assay;IL-2 NK-92 JAK3/JAK1; Used Cellomics detection format.
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
Cell proliferation assay
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
pSTAT5 AlphaScreen assay
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY